Clariant produces first commercial sunliquid® cellulosic ethanol at new plant in Podari, Romania
- After construction completion in October 2021, the plant underwent a thorough commissioning process and has successfully started production
- The offtake of the entire production has been contracted to global energy company Shell for several years
- The flagship plant will process approx. 250,000 tons of straw to produce approx. 50,000 tons of cellulosic ethanol per annum
- The production start at this first sunliquid®cellulosic ethanol plant proves the commercial viability of Clariant’s innovative technologyand with that supports the licensing business strategy
MUTTENZ, JUNE 14, 2022
Clariant, a focused, sustainable, and innovative specialty chemical company, today announced that it has produced the first commercial cellulosic ethanol at its sunliquid® production plant in Podari, Romania1. The entire offtake is contracted with a multi-year agreement to Shell, a leading global energy company. Over the last six months, the plant underwent a thorough commissioning process resulting in the successful start of production. Approximately 50,000 tons of second-generation biofuels will be derived from 250,000 tons of locally sourced agricultural residues. The cellulosic ethanol produced at this plant can be applied as a drop-in solution for fuel blending but also offers further downstream application opportunities for sustainable aviation fuel and bio-based chemicals.
“Protecting the climate is a central part of our purpose ‘Greater chemistry – between people and planet’,” said Conrad Keijzer, Chief Executive Officer at Clariant. “Biofuels and biochemicals made from agricultural waste play a crucial role, since they reduce greenhouse gas emissions. To establish their use more widely, their commercial production and availability must be increased rapidly, which is why the successful start of our sunliquid® plant in Podari is so vital.”
Building a more sustainable future is at the core of what drives Clariant to develop innovative solutions. Christian Librera, Head of Business Line Biofuels & Derivatives added: “The advanced biofuel produced by the sunliquid® technology process supports the decarbonization of the transport sector by providing up to 120 % CO2 savings compared to fossil fuel. It is particularly encouraging to see that despite the global pandemic, we have successfully managed to start production in our flagship sunliquid® cellulosic ethanol plant on schedule. This proves that Clariant's technology is commercially deployable and accelerates our licensing business strategy. I would like to express my sincere thanks to all colleagues and partners involved.”
Shell aims to be a material, profitable supplier of sustainable advanced low-carbon fuels as part of its wider work to become a net-zero emissions energy business by 2050.
“Low-carbon fuels are essential for helping our customers to decarbonize their businesses,” said Geoff Mansfield, General Manager for Low-Carbon Fuels at Shell Trading and Supply.
The plant in Podari, Romania, is built on a 10-hectare area and employs a workforce numbering approximately 100. Contracts have been signed with more than 300 local farmers to ensure the supply of the necessary feedstock.
Learn more about our sunliquid® technology here.
¹The project receives funding from the European Union's Seventh Framework Program for research, technological development and demonstration under Grant Agreement no. 322386 (SUNLIQUID) and from the Circular Bio-based Europe Joint Undertaking under the European Union's Horizon 2020 research and innovation program under Grant Agreement no. 709606 (LIGNOFLAG).
|CORPORATE MEDIA RELATIONS|
Phone +41 61 469 63 63
Phone +41 61 469 63 63
Phone +41 61 469 63 63
Phone +41 61 469 63 73
Phone +41 61 469 63 73
Phone +41 61 469 63 73
|sunliquid® IS A TRADEMARK OF CLARIANT REGISTERED IN MANY COUNTRIES.|
Follow us on Twitter, Facebook, LinkedIn, Instagram.
This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.
Clariant is a focused, sustainable and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2021, the company employed a total workforce of 13 374. In the financial year 2021, Clariant recorded sales of CHF 4.372 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant’s corporate strategy is led by the overarching purpose of ‘Greater chemistry – between people and planet’ and reflects the importance of connecting customer focus, innovation, sustainability, and people.
sunliquid® is an innovative biotechnological method for manufacturing cellulosic ethanol from agricultural residues such as cereal straw, corn stover or sugar cane bagasse. In the completely integrated process, highly optimized, raw material-specific biocatalysts decompose cellulose and hemicellulose in high yields under stable processing conditions into fermentable sugar. The process-integrated production of the biocatalysts offers flexibility and reduces production costs. In the next step, an optimized fermentation organism simultaneously converts C5 and C6 into ethanol with high yields and short reaction times. A highly optimized purification process is instrumental in enabling all the energy required for the process to be derived from the process byproducts like insoluble lignin. Since July 2012, Clariant has been operating a precommercial plant in Straubing, Germany, which produces up to 1,000 metric tons of cellulosic ethanol every year, confirming technical and economic performance. In September 2018, Clariant broke ground for its first-of-its-kind commercial facility in Podari, Romania, which is now completed. Clariant licenses its sunliquid® technology platform globally. So far, license agreements have been signed with renowned industry players in Slovakia, Poland, Bulgaria and China.
- Clariant Media Release Production Start Podari 20220614 EN
- Clariant Media Release Production Start Podari 20220614 DE
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release
REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens
Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release
24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release
With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au
Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo
Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release
EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form